VIENNA – One year after reporting a 75% decrease in acute intermittent porphyria (AIP) attacks from a phase I trial of its RNAi drug, givosiran, Alnylam Pharmaceuticals Inc. returned to the International Liver Congress once again, this time announcing a 74% decrease in its much larger phase III Envision trial.